D. Boral Capital Reiterates “Buy” Rating for Anixa Biosciences (NASDAQ:ANIX)

D. Boral Capital reaffirmed their buy rating on shares of Anixa Biosciences (NASDAQ:ANIX) in a report released on Tuesday morning,Benzinga reports. The brokerage currently has a $10.00 target price on the stock.

Separately, Wall Street Zen raised Anixa Biosciences from a “sell” rating to a “hold” rating in a report on Friday, June 6th. Three research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $9.00.

Anixa Biosciences Stock Performance

NASDAQ:ANIX opened at $2.95 on Tuesday. The stock’s fifty day moving average price is $3.11 and its two-hundred day moving average price is $2.97. Anixa Biosciences has a 52-week low of $2.07 and a 52-week high of $4.20. The company has a market cap of $95.02 million, a price-to-earnings ratio of -8.43 and a beta of 0.58.

Anixa Biosciences (NASDAQ:ANIX) last posted its quarterly earnings data on Wednesday, September 10th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.03. On average, equities analysts predict that Anixa Biosciences will post -0.41 EPS for the current fiscal year.

Insider Buying and Selling at Anixa Biosciences

In related news, Director Lewis H. Titterton, Jr. purchased 10,000 shares of the business’s stock in a transaction dated Thursday, July 31st. The shares were bought at an average price of $3.08 per share, with a total value of $30,800.00. Following the purchase, the director directly owned 953,334 shares in the company, valued at $2,936,268.72. This trade represents a 1.06% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. Over the last 90 days, insiders acquired 35,000 shares of company stock valued at $110,700. Corporate insiders own 25.30% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in ANIX. Focus Partners Wealth acquired a new position in shares of Anixa Biosciences in the 4th quarter valued at $162,000. Jane Street Group LLC acquired a new position in shares of Anixa Biosciences in the 4th quarter valued at $67,000. Private Advisor Group LLC acquired a new position in shares of Anixa Biosciences in the 1st quarter valued at $35,000. Marshall Wace LLP acquired a new position in shares of Anixa Biosciences in the 2nd quarter valued at $39,000. Finally, Benjamin Edwards Inc. acquired a new position in shares of Anixa Biosciences in the 2nd quarter valued at $37,000. Institutional investors and hedge funds own 29.13% of the company’s stock.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.